Sanofi Acquires Blueprint Medicines for $9.1B, Strengthens Rare Immunology Portfolio

Published on Spencer Knight via LinkedIn

Sanofi has announced a definitive agreement to acquire Blueprint Medicines in a $9.1 billion all-cash deal, including a $400 million CVR. The acquisition brings Ayvakit (avapritinib), the only approved treatment for systemic mastocytosis, into Sanofi’s portfolio.

The deal also includes elenestinib and BLU-808, two next-gen KIT inhibitors in development, reinforcing Sanofi’s strategy to lead in precision immunology. Spencer Knight highlights this as another major move following Sanofi’s string of biotech acquisitions in 2024 and 2025, reflecting rising momentum in rare immune disorder innovation.

Read the full post on LinkedIn:

👉 Spencer Knight: Sanofi Makes $9.1B Immunology Acquisition

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.